News

The acquisition of Idenix is expected to expand Merck’s portfolio of investigational therapies for hepatitis C. Merck Research Laboratories president Roger Perlmutter said Idenix has established a promising

Onychomycosis is a common and destructive nail infection that is currently undertreated due to the limitations of available treatments. At present, over-the-counter (OTC) or prescription topical treatments provide

The new indication reflects that AZILECT can be used alone or in combination with other Parkinson’s disease (PD) medications. The approval reinforces the growing clinical evidence demonstrating the

The vaccine is a "therapeutic vaccine" in that it will be used to stimulate the immune system of patients that already suffer from cancer. This is in contrast

Pursuant to this agreement, CELLforCURE will be responsible for the manufacturing of cGMP clinical batches for candidates from Cellectis’ UCART product family. The candidates from UCART (for Universal

Pursuant to this certificate, the USPTO has extended the term of US patent No. 5,861,379 (tesamorelin composition of matter patent) by five years. This patent was originally set

The trial is designed to characterize the safety, tolerability, pharmacokinetics and pharmacodynamics of increasing doses of AG-348 for 14 days. AG-348 is a first-in-class, orally available activator of

Vatiquinone is the International Nonproprietary Name (INN) (or generic name) for the company’s EPI-743 and it is issued by the World Health Organization, which is used to identify

FDA determined that the ANDA is bioequivalent therefore, therapeutically equivalent to the reference listed drug, Cyklokapron – tranexamic acid injection solution. The injection is indicated in hemophilia patients